Beatriz E. Ibanez-Joven
Madrid, MD, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Seventeen-year reassessment of diagnostic transitions, biologic therapy initiation and mortality in spondyloarthritis: results from the REGISPON-3 study.
Journal: RMD open
Published: June 16, 2025
Management of vascular risk in patients with psoriasis in primary care
Journal: Semergen
Published: June 16, 2025
Disease activity in patients with idiopathic inflammatory myopathy according to time since diagnosis and positivity to antisynthetase autoantibodies: data from the Myo-Spain registry.
Journal: Arthritis research & therapy
Published: August 19, 2024
Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from Spain.
Journal: Frontiers in immunology
Published: August 25, 2023
Moderate-High Disease Activity in Patients with Recent-Onset Psoriatic Arthritis-Multivariable Prediction Model Based on Machine Learning.
Journal: Journal of clinical medicine
Published: November 25, 2022
Improvement in patient-reported outcomes and work productivity following 3-year ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: results from the PsABio real-world study.
Journal: Arthritis research & therapy
Published: November 22, 2022
Gender-specific differences in patients with psoriatic arthritis receiving ustekinumab or tumour necrosis factor inhibitor: real-world data.
Journal: Rheumatology (Oxford, England)
Published: October 05, 2022
Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study.
Journal: Annals of the rheumatic diseases
Published: June 01, 2022
Severe Disease in Patients With Recent-Onset Psoriatic Arthritis. Prediction Model Based on Machine Learning.
Journal: Frontiers in medicine
Published: March 08, 2022
Confounders contributing to explain the association between sex and disease impact in patients with recent-onset psoriatic arthritis.
Journal: Clinical and experimental rheumatology
Published: March 03, 2022
Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study.
Journal: Annals of the rheumatic diseases
Published: October 08, 2021
Last Updated: 09/26/2026